NITAG recommendations

To be administered five to six months after the second booster, in persons over 65, immunosuppressed persons over 65, immunosuppressed persons, chronically ill persons and health care workers with chronic diseases. Preferably, administer the SARS-CoV-2 messenger RNA-based platform vaccine. In cases where there is contraindication to a messenger RNA-based vaccine, use a different platform vaccine.  

Catch-up: Reinforce the message to the population and the deployment of resources for the completion of primary vaccination schedules and first and second boosters for the entire beneficiary population, aiming for most of the target population to be vaccinated with two boosters with anti-SARS-CoV-2 mRNA-based vaccine.  

Monitor the epidemiological situation of COVID-19 and the effectiveness of SARS-CoV-2 vaccination for the timely detection of signs indicating the emergence of an increased risk of severe COVID-19 among vaccinated persons. In this situation, a third booster dose can be considered for the general population or special risk populations.  

Strengthen risk communication considering the latest prevention and control measures framework which have relaxed the use of facemasks among other measures.  

Continue to grow, develop, and strengthen the vaccine pharmacovigilance system for vaccines.